Kepler Capital Maintains a Hold Rating on GSK plc (GSK)

GSK plc (NYSE:GSK) is one of the best growth stocks under $50 to buy now. In a report released on September 4, David Evans from Kepler Capital maintained a Hold rating on GSK plc (NYSE:GSK), setting a price target of p1,500.00.

Is GSK plc (GSK) the Best Undervalued UK Stock to Buy Right Now?

GSK plc (NYSE:GSK) released its fiscal Q2 2025 earnings on July 30, reporting total sales of £8.0 billion. Total operating profit for the quarter rose 33% while total EPS increased by 35%, driven by lower CCL charges.

GSK plc (NYSE:GSK) also reported £2.4 billion in cash generated from operations, with free cash flow of £1.1 billion.

Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global healthcare and biopharmaceutical corporation that develops and distributes a range of vaccines, medications, and consumer health items. It is based in the United Kingdom and has over 20 vaccines in its portfolio, positioning it as a leader in vaccines, immunology, and respiratory therapies. The company also develops cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer in addition to other drugs.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.